/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Moderna (MRNA), once an unknown biotech firm, quickly rose to the top of the global vaccine market during the COVID-19 pandemic. Its mRNA technology platform created one of the world’s first and most widely used COVID-19 vaccines.
Investors who recognized its potential early saw a dramatic increase in share price, with MRNA stock rising by 1,226.9% between 2020 and 2022.